Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health

Published by international research collaboration in Nature Biotechnology

PARIS and CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, notes a new academic publication describing the creation of the most comprehensive and unified catalog to-date of genomic and proteomic data from the human gut microbiome.

The publication in Nature Biotechnology (Almeida, et al, ref. 1), reports on the establishment of a catalog of more than 200,000 reference genomes from over 4,600 species of human gut bacteria.

The research was conducted by an international collaboration involving major academic institutes, such as the European Bioinformatics Institute (UK), Sanger Institute (UK), University of California, San Francisco (USA), Chan Zuckerberg BioHub (USA), University of Trento (Italy), University of Queensland (Australia), Joint Genome Institute (USA) and Enterome (France).

These reference catalogs build on previous global projects aimed at characterizing the human gut microbiome (such as the Human Microbiome Project). The goal of this research is to enable a better understanding of the functions and interactions of bacterial species in the gut microbiome and link to their roles in human health – linking genotype to phenotype within specific clinical contexts, such as during inflammatory diseases, metabolic diseases and cancer.

Enterome has further expanded on this work to assemble the most comprehensive and annotated dataset of peptides and proteins from the gut microbiome (Enterome's MetaSecretome dataset). This dataset underpins Enterome's proprietary OncoMimics and EndoMimics platforms, which are being applied to identify and develop novel orally administered, potent and well-tolerated next-generation therapeutics.

Christophe Bonny, Chief Scientific Officer of Enterome, said: "Enterome has a wealth of expertise and powerful technologies designed to explore and analyze the functional content of the human gut microbiome. We are focused on applying our expertise and tools to address in silico large-scale data analysis of microbiome genes and proteins to develop novel drugs for major diseases. We are thrilled that these capabilities have been recognized by our prestigious collaboration partners, and that we have been able to contribute to these important new genomic and proteomic resources. We are confident that these new resources will contribute to an even better understanding of how to leverage the influence of the gut microbiome to improve human health."

Reference

1.  Almeida, A., Nayfach, S., Boland, M. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0603-3

Contacts 

Enterome
Pierre Belichard, CEO
Tel. +33 1 75 77 27 87
media@enterome.com

Media Relations
Mark Swallow / Sylvie Berrebi / David Dible
Citigate Dewe Rogerson
Tel. +44 207 638 9571
enterome@citigatedewerogerson.com

Investor Relations
Melody Carey
Rx Communications Group
Tel. +1 917 322 2571/ mcarey@rxir.com

About Enterome

Enterome is a world leader in the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system (the 'microbiome-immunoinflammation axis'). Enterome is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.

Enterome has two unique platforms that are generating highly promising drug candidates:

-  OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and expected to enter first clinical trials in patients with adrenal malignancies during mid-2020. EO2463, is being prepared as a clinical candidate for B-cell malignancies.

-  EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.

These highly productive platforms have been created using Enterome's world-leading Metasecretome technology, which gives it an unrivalled ability to generate precision drugs by using the natural reservoir of thousands of safe and tolerized effector proteins that are produced by the gut bacteria.

Enterome's most advanced drug candidate is EB8018 (also referred to as sibofimloc/TAK-018), which selectively blocks the virulence factor FimH, is advancing through clinical trials in Crohn's disease. EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed by leading venture capital investors.

For more information please visit the company's website at: www.enterome.com

SOURCE Enterome